Complete Conference Management 26th Annual San Diego Heart Failure Winter Symposium 2026

Description

+ Include: 53 videos + 53 file sub vtt + 40 pdfs, size: 17.36 GB

+ Target Audience: cardiologists, internists, primary care physicians, family medicine physicians

+ Sample video: contact me for sample video

+ Information:

26th Annual San Diego Heart Failure Winter Symposium: New Strategies for Detection, Prevention and Treatment of Heart Failure is organized by Complete Conference Management (CCM) and will be held from Jan 23 – 24, 2026 at Hilton La Jolla Torrey Pines, La Jolla, California, United States of America.

This year’s 26th Annual San Diego Heart Failure Winter Symposium – New Strategies for Detection, Prevention and Treatment of Heart Failure on January 23 & 24, 2026 aims to provide a comprehensive overview of how to best manage patients with heart failure at all stages of disease. This accredited program emphasizes practical aspects of heart failure management beginning with prevention of clinically manifest disease in patients at risk and extending to end-stage heart failure. Over the course of two days, the focused sessions that include lectures, case discussions and moderated panels will provide expert insight and personal experience that cover the full range of management options that are available for managing patients throughout the spectrum of heart failure. The agenda of the Winter 2026 Symposium includes content that extends from recognition of patients with cardiovascular-renal-metabolic syndrome (CRMS) who are risk of developing heart failure to the management of patients with symptomatic heart failure including those with cardiogenic shock or end-stage disease. Advances in drug and device therapy will receive extensive coverage throughout the Symposium. Insights into the recognition and management of less common (but not less important) causes of disease including genetic mutations are important areas that will be reviewed. Throughout the Symposium, best practices and emerging strategies for diagnosis and treatment are emphasized. By combining case vignettes, patient narratives, didactic lectures and insightful panel discussions, attendees will have the opportunity to gain state of the art insights into the management of patients with heart failure. Our goal, as always, is to provide cutting edge information in a format that will enhance adaption of the knowledge that is gained into clinical practice..

SYMPOSIUM OBJECTIVES:

• Summarize current and emerging treatments available for preventing and treating heart failure and provide information to help in the selection of the most effective choices in individual patients.
• Review strategies for implementing medical and device therapies that will lead to improved outcomes in heart failure patients.
• Define how specific populations including minorities, women and the elderly respond to various approaches to treating risk factors and heart failure.

TARGET AUDIENCE

This course is designed for cardiologists, internists, primary care physicians, nurses, PA’s, PharmD’s and all other allied healthcare professionals with an interest in heart failure.

 

+ Topics:

• 01 Recognizing the Cardio-Renal-Metabolic Syndrome (CRMS) and It’s Importance in Practice

• 02 Role of SGLT2 Inhibitors in Treating Patients with DCRM Conditions

• 03 Emerging Evidence that GLP-1 Agonists Can Prevent CV Disease in Patients with CRMS

• 04 Advances in the Management of Patients with Dyslipidemia

• 05 Use of Finerenone To Prevent CV Disease, CKD and Heart Failure

• 06 Moderated Panel

• 07 Percutaneous Valve Replacement and Repair

• 08 Advances in the Management of Pulmonary Arterial Hypertension

• 09 Recognizing and Treating Patients with Amyloidosis

• 10 Advances in the Management of Patients with Hypertrophic Cardiomyopathy

• 11 Managing Patients with Cardiac Sarcoidosis and Other Infiltrative Diseases

• 12 Moderated Panel Discussion

• 13 Introduction to Rare Diseases and Gene Therapy

• 14 Gene Therapy from Bench to Bedside

• 15 Genetic Testing – Who, What, When and Why

• 16 Genetic Counseling

• 17 Gene Therapy for Genetic Cardiomyopathies

• 18 Gene Therapy for Lysosomal Storage Diseases

• 19 Genetic Diseases from the Patient Perspective

• 20 Moderated Panel Discussion – Session 4

• 21 Advances in the Management of Patients with Symptomatic HFrEF

• 22 Emerging Approaches for Managing Patients with Symptomatic HFpEF

• 23 Monitoring Devices To Identify and Treat Congestion

• 24 What’s New in 2026

• 25 Moderated Panel Discussion – Session 5

• 26 Recognizing Preshock-The Early Warning Signs

• 27 Diagnosis and Initial Management of Cardiogenic Shock

• 28 Mechanical Circulatory Support in Escalating Shock

• 29 Surgical Intervention for Advanced Cardiogenic Shock

• 30 Moderated Panel Discussion – Session 6

• 31 Emerging Approaches for Categorizing and Treating Patients with Myocarditis and Chronic Pericarditis

• 32 Approaches for Managing Patients with Atrial Fibrillation and Preventing Thromboembolism

• 33 Chemotherapy Induced Cardiomyopathy- Prevalence, Risk and Prevention

• 34 Identifying Patients at Risk of Sudden Cardiac Death

• 35 Who Is A Candidate for Advanced Therapies

• 36 Outcomes From Cardiac Transplantation and LVAD

• 37 Moderated Panel Discussion – Session 8

• 38 Case Vignettes Cardiogenic shock in pregnancy

• 39 Clinical Vignettes Wettersten_Case

• 40 Case Vignettes Dixit_Case

• 41 Case Vignettes Shen_Case

• 42 Case Vignettes Taub_Cases

• 43 Case Vignettes

• Case Vignettes Day 1

• Clinical Vignettes Day 2

• Session I-Defining and Managing the Cardio-Renal-Metabolic Syndrome

• Session II- Cardio-Oncology and Pulmonary Arterial Hypertension

• Session III- Amyloid and Other Infiltrative Heart Disease, Hypertrophic Cardiomyopathy and HFpEF

• Session IV- Rare Diseases and Gene Therapy

• Session V- Managing Patients with Stage C Heart Failure

• Session VI- Shock and Pre-Shock- Diagnosis and Management

• Session VII- Myocarditis, Pericarditis, Arrhythmias, Treating Valvular Heart Disease and Preventing Sudden Cardiac…

• Session VIII- Advanced Therapies for Heart Failure